QCG
ASMB icon

Quadrant Capital Group’s Assembly Biosciences ASMB Stock Holding History

Quadrant Capital Group’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-22
Closed -$749 – 2712
2025
Q4 		$749 Hold
22
– – ﹤0.01% 2619
2025
Q3 		$564 Buy
+22
New +$483 ﹤0.01% 2599

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Quadrant Capital Group's ASMB Position: Q1 2026 in Review

Quadrant Capital Group sold out of Assembly Biosciences (ASMB) in Q1 2026, closing a stake of 22 shares — an estimated $749 sold.

Quadrant Capital Group first reported a position in ASMB in Q3 2025 and held it in 2 quarters. The position peaked at $749 in Q4 2025. 75 funds tracked by Wall St. Rank hold ASMB as of Q1 2026.

  • Quadrant Capital Group reported no remaining Assembly Biosciences position as of Q1 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 22 Assembly Biosciences shares in Q1 2026, an estimated $749.
  • Quadrant Capital Group first reported a position in Assembly Biosciences in Q3 2025 and held it in 2 quarters.
  • Quadrant Capital Group's Assembly Biosciences position peaked at $749 in Q4 2025.
  • 75 funds tracked by Wall St. Rank held Assembly Biosciences as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.